n-octyl-beta-valienamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-octyl-beta-valienamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9817381
CHEMBL ID	1234952
CHEMBL ID	1922580
SCHEMBL ID	21067585
MeSH ID	M0299563

Synonyms (10)

Synonym
CHEMBL1234952
n-octylvalienamine
(1s,2s,3r,6r)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol
oev ,
DB08321
CHEMBL1922580 ,
bdbm50358322
n-octyl-beta-valienamine
Q27097540
SCHEMBL21067585

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay ID	Title	Year	Journal	Article
AID731602	Induction of beta glucosidase F213I/L444P mutant activity in fibroblasts derived from Gaucher disease patient after 4 days relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731601	Induction of beta glucosidase N370S mutant activity in fibroblast derived from Gaucher disease patient relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731603	Induction of beta glucosidase F213I mutant activity in fibroblasts derived from Gaucher disease patient at 30 uM after 4 days relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731600	Induction of beta glucosidase L444P mutant activity in fibroblast derived from Gaucher disease patient relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731641	Induction of wild type beta glucosidase activity in fibroblasts derived from Gaucher disease patient after 4 days relative to control	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Pharmacological chaperones as therapeutics for lysosomal storage diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (4.76)	18.2507
2000's	7 (33.33)	29.6817
2010's	13 (61.90)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.30 (24.57)
Research Supply Index	3.14 (2.92)
Research Growth Index	5.43 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.30)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	3 (13.64%)	6.00%
Case Studies	1 (4.55%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (81.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.77	3	cyclitol; hexol
ambroxol Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.	3.18	1	aromatic amine
galactose galactopyranose : The pyranose form of galactose.	3.18	1	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
aniline [no description available]	2.06	1	anilines; primary arylamine
methylene chloride Methylene Chloride: A chlorinated hydrocarbon that has been used as an inhalation anesthetic and acts as a narcotic in high concentrations. Its primary use is as a solvent in manufacturing and food technology.. dichloromethane : A member of the class of chloromethanes that is methane in which two of the hydrogens have been replaced by chlorine. A dense, non-flammible colourless liquid at room temperature (b.p. 40degreeC, d = 1.33) which is immiscible with water, it is widely used as a solvent, a paint stripper, and for the removal of caffeine from coffee and tea.	2.06	1	chloromethanes; volatile organic compound	carcinogenic agent; polar aprotic solvent; refrigerant
cyclohexane Cyclohexane: C6H12. cyclohexane : An alicyclic hydrocarbon comprising a ring of six carbon atoms; the cyclic form of hexane, used as a raw material in the manufacture of nylon.	2.06	1	cycloalkane; volatile organic compound	non-polar solvent
ecdysone [no description available]	2.06	1	14alpha-hydroxy steroid; 22-hydroxy steroid; 25-hydroxy steroid; 2beta-hydroxy steroid; 3beta-sterol; 6-oxo steroid; ecdysteroid	prohormone
ammonium chloride Ammonium Chloride: An acidifying agent that has expectorant and diuretic effects. Also used in etching and batteries and as a flux in electroplating.. ammonium chloride : An inorganic chloride having ammonium as the counterion.	2.05	1	ammonium salt; inorganic chloride	ferroptosis inhibitor
1-deoxynojirimycin 1-deoxy-nojirimycin: structure in first source. duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.	3.88	3	2-(hydroxymethyl)piperidine-3,4,5-triol; piperidine alkaloid	anti-HIV agent; anti-obesity agent; bacterial metabolite; EC 3.2.1.20 (alpha-glucosidase) inhibitor; hepatoprotective agent; hypoglycemic agent; plant metabolite
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	3.18	1	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	3.18	1	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
castanospermine castanospermine: indolizidine alkaloid from seeds of Australian legume, Castanospermum australe. castanospermine : A tetrahydroxyindolizidine alkaloid that consists of octahydroindolizine having four hydroxy substituents located at positions 1, 6, 7 and 8 (the 1S,6S,7R,8R,8aR-diastereomer).	3.18	1	indolizidine alkaloid	anti-HIV-1 agent; anti-inflammatory agent; EC 3.2.1.* (glycosidase) inhibitor; metabolite
nojirimycin nojirimycin: from Streptomyces ficellus; RN given refers to parent cpd without isomeric designation	2.1	1	amino monosaccharide; hydroxypiperidine
lobeline (-)-lobeline : An optically active piperidine alkaloid having a 2-oxo-2-phenylethyl substituent at the 2-position and a 2-hydroxy-2-phenylethyl group at the 6-position.	3.18	1	aromatic ketone; piperidine alkaloid; tertiary amine	nicotinic acetylcholine receptor agonist
2-acetamido-1,5-imino-1,2,5-trideoxy-d-glucitol 2-acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol: structure given in first source	3.18	1
homonojirimycin homonojirimycin: inhibits alpha-glucosidase; RN given for (2R-(2alpha,3alpha,4beta,5alpha,6beta))-isomer; structure in first source	3.18	1
migalastat migalastat: a potent inhibitor of glycolipid biosynthesis	3.59	2	piperidines
valienamine valienamine: intermediate formed by microbial degradation of validamycins; structure given in first source	3.56	2
glucosamine D-glucosamine : An amino sugar whose structure comprises D-glucose having an amino substituent at position 2.. 2-amino-2-deoxy-D-glucopyranose : A D-glucosamine whose structure comprises D-glucopyranose having an amino substituent at position 2.	3.18	1	D-glucosamine	Escherichia coli metabolite; geroprotector; mouse metabolite
vibo-quercitol vibo-quercitol: structure in first source	2.06	1
isofagomine [no description available]	3.18	1	piperidines
n-nonyl-1-deoxynojirimycin N-nonyldeoxynojirimycin : A hydroxypiperidine that is deoxynojirimycin (duvoglustat) in which the amino hydrogen is replaced by a nonyl group.	3.18	1	hydroxypiperidine; tertiary amino compound	antiviral agent; EC 3.2.1.20 (alpha-glucosidase) inhibitor; EC 3.2.1.45 (glucosylceramidase) inhibitor
4-(benzenesulfonamido)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)benzamide [no description available]	3.18	1	sulfonamide
N-[4-methyl-2-(4-morpholinyl)-6-quinolinyl]cyclohexanecarboxamide [no description available]	3.18	1	aminoquinoline
n-acetylglucosamine thiazoline N-acetylglucosamine thiazoline: an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid	3.18	1

Condition	Relationship Strength	Studies
Lysosomal Enzyme Disorders [description not available]	3	1
Adult GM1 Gangliosidosis [description not available]	5.06	9
Gangliosidosis, GM1 An autosomal recessive neurodegenerative disorder caused by the absence or deficiency of BETA-GALACTOSIDASE. It is characterized by intralysosomal accumulation of G(M1) GANGLIOSIDE and oligosaccharides, primarily in neurons of the central nervous system. The infantile form is characterized by MUSCLE HYPOTONIA, poor psychomotor development, HIRSUTISM, hepatosplenomegaly, and facial abnormalities. The juvenile form features HYPERACUSIS; SEIZURES; and psychomotor retardation. The adult form features progressive DEMENTIA; ATAXIA; and MUSCLE SPASTICITY. (From Menkes, Textbook of Child Neurology, 5th ed, pp96-7)	5.06	9
Eccentro-Osteochondrodysplasia [description not available]	2.76	3
Mucopolysaccharidosis IV Genetic disorder of mucopolysaccharide metabolism characterized by skeletal abnormalities, joint instability, development of cervical myelopathy, and excessive urinary keratan sulfate. There are two biochemically distinct forms, each due to a deficiency of a different enzyme.	2.76	3
Classic Globoid Cell Leukodystrophy [description not available]	2.11	1
Leukodystrophy, Globoid Cell An autosomal recessive metabolic disorder caused by a deficiency of GALACTOSYLCERAMIDASE leading to intralysosomal accumulation of galactolipids such as GALACTOSYLCERAMIDES and PSYCHOSINE. It is characterized by demyelination associated with large multinucleated globoid cells, predominantly involving the white matter of the central nervous system. The loss of MYELIN disrupts normal conduction of nerve impulses.	2.11	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.05	1
Acid beta-Glucosidase Deficiency [description not available]	2.73	3
Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.	2.73	3
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.07	1
Malignant Melanoma [description not available]	1.99	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.99	1

chemdatabank.com